

Marco Ventimiglia

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4056740/marco-ventimiglia-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

219
citations

9
h-index

13
g-index

26
ext. papers

340
ext. citations

3.2
avg, IF

2.98
L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 25 | The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018 , 50, 675-681 | 3.3 | 22 |
| 24 | A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor- α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 209-217 | 1.5 | 19 |
| 23 | The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 182-189 | 4.5 | 19 |
| 22 | Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 193-203 | 5.4 | 16 |
| 21 | Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 981-987 | 2.4 | 15 |
| 20 | Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1950-1961 | 5.6 | 12 |
| 19 | Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020 , 37, 383-392 | 4.7 | 12 |
| 18 | A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018 , 50, 1292-1298 | 3.3 | 11 |
| 17 | Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 987-997 | 4.5 | 10 |
| 16 | The Addition of an Immunosuppressant After Loss of Response to Anti-TNF Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 394-401 | 4.5 | 9 |
| 15 | Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1045-1055 | 5.3 | 8 |
| 14 | Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 234-236 | 6.1 | 8 |
| 13 | Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020 , 101, 433-440 | 3.6 | 8 |
| 12 | A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 105-111 | 4 | 7 |
| 11 | Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021 , 5, 364-370 | 1.8 | 7 |
| 10 | Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1102-1106 | 2.4 | 6 |
| 9 | A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020 , 52, 1461-1466 | 3.3 | 5 |

| | | | |
|---|--|-----|---|
| 8 | Pouchitis in pediatric ulcerative colitis: A multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. <i>Digestive and Liver Disease</i> , 2019 , 51, 1551-1556 | 3-3 | 5 |
| 7 | Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020 , 52, 1304-1309 | 3-3 | 5 |
| 6 | Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 223-229 | 2-4 | 5 |
| 5 | Health-Related Quality of Life and Home Enteral Nutrition in Children with Neurological Impairment: Report from a Multicenter Survey. <i>Nutrients</i> , 2019 , 11, | 6-7 | 4 |
| 4 | How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018 , 50, 734-736 | 3-3 | 2 |
| 3 | Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1381-1384 | 5-4 | 2 |
| 2 | Caregiver Social Status and Health-Related Quality of Life in Neurologically Impaired Children on Home Enteral Nutrition. <i>Nutrients</i> , 2021 , 13, | 6-7 | 1 |
| 1 | SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3041-3049 | 4 | 1 |